Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review  by Koti, Rahul S. et al.
REVIEW ARTICLE
Meta-analysis of randomized controlled trials on the
effectiveness of somatostatin analogues for pancreatic surgery:
a Cochrane review
Rahul S. Koti, Kurinchi S. Gurusamy, Giuseppe Fusai & Brian R. Davidson
Department of Surgery, Royal Free Hospital and University College School of Medicine, Royal Free Hospital, London, UK
Abstracthpb_157 155..165
Background: The use of synthetic analogues of somatostatin following pancreatic surgery is contro-
versial. The aim of this meta-analysis is to determine whether prophylactic somatostatin analogues (SAs)
should be used routinely in pancreatic surgery.
Methods: Randomized controlled trials were identified from the Cochrane Library Trials Register,
MEDLINE, EMBASE, Science Citation Index Expanded and reference lists. Data were extracted from
these trials by two independent reviewers. The risk ratio (RR), mean difference (MD) and standardized
mean difference (SMD) were calculated with 95% confidence intervals (95% CIs) based on intention-to-
treat or available case analysis.
Results: Seventeen trials involving 2143 patients were identified. The overall number of patients with
postoperative complications was lower in the SA group (RR 0.71, 95% CI 0.62–0.82), but there was no
difference between the groups in perioperative mortality (RR 1.04, 95% CI 0.68–1.59), re-operation rate
(RR 1.15, 95% CI 0.56–2.36) or hospital stay (MD -1.04 days, 95% CI -2.54 to 0.46). The incidence of
pancreatic fistula was lower in the SA group (RR 0.64, 95% CI 0.53–0.78). The proportion of these fistulas
that were clinically significant is not clear. Analysis of results of trials that clearly distinguished clinically
significant fistulas revealed no difference between the two groups (RR 0.69, 95% CI 0.34–1.41). Subgroup
analysis revealed a shorter hospital stay in the SA group than among controls for patients with malignant
aetiology (MD -7.57 days, 95% CI -11.29 to -3.84).
Conclusions: Somatostatin analogues reduce perioperative complications but do not reduce periop-
erative mortality. However, they do shorten hospital stay in patients undergoing pancreatic surgery for
malignancy. Further adequately powered trials of low risk of bias are necessary.
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Introduction
Pancreatic resection is performed to treat pancreatic diseases
including malignancy and chronic pancreatitis. In most series, the
incidence of complications following pancreatic surgery varies
from 30% to 60% and the mortality rate is <5%.1–3 The major
complication following pancreatic resection is postoperative pan-
creatic leak or fistula. Recent reviews have described the incidence
of pancreatic leak or fistula as 37%.4 Various methods have been
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suggested to decrease the incidence of pancreatic complications,
but the most common approach has involved the use of soma-
tostatin or its synthetic analogues. Somatostatin and its analogues
decrease the exocrine and endocrine pancreatic secretions by
binding to the somatostatin receptors on the exocrine and endo-
crine cells, and decrease the secretions of these cells possibly by
acting as dephosphorylators and by altering the calcium transport
across the cell membranes.5 Decreasing the volume of pancreatic
secretion may decrease the incidence of pancreatic leak or fistula.6
However, the use of somatostatin and its analogues is controver-
sial and whereas some randomized controlled trials (RCTs) and
systematic reviews recommend7,8 prophylactic somatostatin ana-
logues (SAs) in pancreatic resections, others do not.9,10 These
treatments may potentially decrease morbidity and mortality fol-
lowing pancreatic surgery, but it is possible that they may have no
therapeutic benefit and may be associated with negative out-
comes. A systematic review was carried out to determine
whether prophylactic SAs should be used routinely in pancreatic
surgery.
Materials and methods
Identification of trials and data extraction
Only RCTs of parallel design, irrespective of blinding, sample size,
publication status (i.e. whether published as full text or presented
only as an abstract at a conference) and language, were included.
Quasi-randomized trials and other study designs were excluded.
Only trials involving patients undergoing a pancreatic surgical
procedure (pancreatic resection, pancreatic duct drainage proce-
dures or cyst drainage procedures) for any pancreatic disease were
considered. Only trials involving the administration of periopera-
tive somatostatin (or an analogue of this hormone, such as oct-
reotide) against a comparator of placebo or no intervention were
considered. The Cochrane Upper Gastrointestinal and Pancreatic
Diseases Group Controlled Trials Register,11 the Cochrane Central
Register of Controlled Trials (CENTRAL) in the Cochrane
Library, MEDLINE, EMBASE and Science Citation Index
Expanded12 were searched for trials published up to November
2009. The references of the identified trials were also searched to
identify further relevant trials.
Two reviewers (RSK and KSG) independently identified the
trials for inclusion. In addition, the population characteristics
(such as sex, age, proportion of pancreaticoduodenectomies,
disease aetiology) and the interventions used in each trial were
extracted. The methodological qualities of the trials were assessed
independently, without masking the trial names. Any unclear or
missing information was obtained by contacting the authors of
the individual trials. If there was any doubt as to whether trials had
shared the same patients – completely or partially (by identifying
common authors and centres) – the authors of the trials were
contacted to establish whether the trial report had been
duplicated. Any differences in opinion were resolved through
discussion.
Outcomes
Data for the following outcomes were extracted: postoperative
mortality; re-operation; postoperative complications (anasto-
motic leak, pancreatic fistula, pancreatitis, sepsis, renal failure,
bleeding, abdominal collections, infected abdominal collections,
delayed gastric emptying, pulmonary complications, shock,
number of complications, number of patients with any compli-
cations); drug-related complications (treatment withdrawal,
number with adverse effects resulting from treatment), and hos-
pital stay (total hospital stay, intensive care unit [ICU] stay).
Pancreatic fistula has been graded as A, B and C by consensus
amongst surgeons.13 Any pancreatic fistula, however defined, was
included by the authors as one of the outcomes. Clinically sig-
nificant pancreatic fistula was included as another outcome, for
which only trials which featured data on grades B and C
as distinct from grade A (not clinically significant) were
included.
Subgroup analyses of trials with low risk of bias vs. those with
high risk of bias, different interventions (somatostatin and oct-
reotide), different aetiologies (malignancy and chronic pan-
creatitis), different procedures (pancreatoduodenectomy, distal
pancreatectomy and pancreatic drainage procedures) and differ-
ent methods of management of the pancreatic stump (pancreato-
gastrostomy and pancreatojejunostomy) were planned.
Assessment of risk of bias
Risk of bias can result in the incorrect estimation of the effective-
ness of an intervention.14–17 The risk of bias in the trials was
assessed in different domains, including sequence generation,
allocation concealment, blinding (of participants, personnel and
outcome assessors), incomplete outcome data, selective outcome
reporting and other sources of bias, such as baseline imbalance,
early stopping bias, academic bias and sources of funding bias.18,19
Trials which were classified as being at low risk of bias in sequence
generation, allocation concealment, blinding, incomplete data
and selective outcome reporting were considered as low bias-risk
trials.
Statistical methods
Meta-analyses were performed according to the recommenda-
tions of the Cochrane Collaboration18 using the software
package Revman 5.0 (Nordic Cochrane Centre, Cochrane Col-
laboration, Copenhagen, Denmark). For dichotomous outcomes,
the risk ratio (RR) was calculated with a 95% confidence interval
(CI). For continuous outcomes, the mean difference (MD) or
standardized mean difference (SMD) was calculated with its
95% CI. A random-effects model20 and a fixed-effect model21
were used. In cases of discrepancy between the two models, both
the results were reported; otherwise only the results from the
fixed-effect model were reported. The analysis was performed
on an ‘intention-to-treat’ basis22 whenever possible, but, in
order to allow for dropouts and withdrawals between random-
ization and intervention or control, the ‘available case analysis’18
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was adopted. The degree of heterogeneity was measured by chi-
squared test with significance set at a P-value of 0.10, and the
quantity of heterogeneity was measured by I2.23 An I2 value
>30% was considered to represent statistically significant hetero-
geneity. Standard deviation was imputed from standard error or
from P-values if it was not given directly in the trial
reports, according to Cochrane Collaboration guidelines.18
The chi-squared test for subgroup differences set at a
P-value of 0.05 was performed to identify any subgroup
differences.
A funnel plot was used to explore bias.24,25 Asymmetry in the
funnel plot of trial size against treatment effect was used to assess
the risk of bias. The linear regression approach was performed to
determine the funnel plot asymmetry.24
Results
Description of studies
A total of 742 references were identified through electronic
searches of the Cochrane Upper Gastrointestinal and Pancreatic
Diseases Group Controlled Trials Register11 and the Cochrane
Central Register of Controlled Trials (CENTRAL) in the
Cochrane Library (n = 74), MEDLINE (n = 390), EMBASE
(n = 176), Science Citation Index Expanded (n = 102). A total of
192 duplicates and 505 clearly irrelevant references identified by
reading the abstracts were excluded (Fig. 1). Forty-five references
were retrieved for further assessment. No references were iden-
tified through scanning the reference lists of the RCTs
identified. Of the 45 references, 16 were excluded because they
referred to quasi-randomized studies, prospective non-
randomized studies or comments that did not contain data from
an RCT. Of the remaining 29 references, 12 were multiple
reports, which resulted in the identification of a total of 17 RCT
reports which fulfilled the inclusion criteria. All 17 trials were
completed trials and were able to provide data for the analyses.
Important details of the included trials are shown in
Table 1. Only two trials were considered to be at low risk of
bias.26,27
Participants
The 17 trials included 2143 patients (Table 1). A total of 237
patients were involved in six trials comparing somatostatin vs.
control27–32 and 1564 patients were involved in 10 trials comparing
octreotide vs. control.7,8,10,27,33–38 The remaining patients were
involved in one trial comparing vapreotide vs. control.9 Overall,
1457 patients underwent pancreatoduodenectomy, 1143 patients
had malignancy and 587 had chronic pancreatitis in the trials that
reported these characteristics. The mean age of the individuals in
the trials varied between 43 years and 65 years. The mean propor-
tion of females varied between 15% and 48%. There was no dif-
ference in the characteristics of patients in the intervention and
control groups in any of the trials that reported these baseline
characteristics.
References identified through
electronic searches of databases
n = 742 References excluded
Duplicates
Irrelevant by reading titles
and abstracts
n = 697
n = 192
n = 505
References excluded
Quasi-randomized
Non-randomized
Comments/reviews
Out of scope
Awaiting assessment
n = 16
n = 2
n = 4
n = 5
n = 3
n = 2
RCTs withdrawn
by outcome
n = 0
Multiple reports n = 12
References retrieved for more
detailed evaluation
n = 45
Potentially appropriate RCT
to be included
n = 29
References included in
meta-analysis
n = 29
RCTs included in
meta-analysis
n = 17
Figure 1 Flow chart showing the search strategy used to identify trials. RCT, randomized controlled trial
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Somatostatin analogues vs. no intervention
Primary outcomes
There was no difference between the two groups in either perio-
perative mortality (RR 1.04, 95% CI 0.68–1.59) or re-operation
rates (RR 1.15, 95% CI 0.56–2.36) (Fig. 2).
Secondary outcomes
Postoperative complications There were statistically signifi-
cant lower incidences of pancreatic fistula (RR 0.64, 95% CI 0.53–
0.78) (Fig. 3) and sepsis (RR 0.47, 95% CI 0.23–0.97) in the SA
group than in the control group. Likewise, decreases in the
numbers of complications (rate ratio 0.72, 95% CI 0.61–0.85) and
of patients with any complication (RR 0.71, 95% CI 0.62–0.82) in
the SA group over the control group were statistically significant
(Fig. 4). There were no differences between the groups in inci-
dences of anastomotic leak rates (RR 0.81, 95% CI 0.51–1.27),
clinically significant pancreatic fistulas (RR 0.69, 95% CI 0.34–
1.41) (Fig. 3), postoperative pancreatitis (RR 0.63, 95% CI 0.32–
1.22), renal failure (RR 0.67, 95% CI 0.25–1.77), bleeding (RR
1.00, 95% CI 0.70–1.44), abdominal collections (RR 0.79, 95% CI
0.58–1.09), infected abdominal collections (RR 0.97, 95% CI
0.68–1.38), delayed gastric emptying (RR 0.81, 95% CI 0.52–
1.28), pulmonary complications (RR 0.86, 95% CI 0.54–1.36) or
shock (RR 0.92, 95% CI 0.41–2.05).
Drug-related complications There was no difference in treat-
ment withdrawal (RR 1.55, 95% CI 0.56–4.33) or number of
patients with adverse effects caused by treatment (RR 1.27, 95%
CI 0.95–1.71) between the groups.
Hospital stay There was no difference in the duration of hospital
stay (MD -1.04, 95% CI -2.54 to 0.46) or ICU stay (MD 0.90, 95%
CI -1.76 to 3.56) between the groups.
Subgroup analysis
The following planned subgroup analyses were performed: differ-
ent interventions (somatostatin and octreotide); different aetiolo-
gies (malignancy and chronic pancreatitis), and different
procedures (pancreatoduodenectomy). A planned subgroup
analysis of other procedures (distal pancreatectomy and pancre-
atic drainage procedures), and the different methods of manage-
ment of pancreatic stump (pancreatogastrostomy and
pancreatojejunostomy) could not be performed as the outcome
data for the different subgroups were not available from the trials.
Subgroup analysis based on the risk of bias in the trials could
not be performed as only two trials were at low risk of bias.26,27
There was no difference in any of the primary outcomes between
intervention and control groups in the different subgroups.
The secondary outcomes for which there were statistically sig-
nificant differences between the two groups are described below.
Stratified by intervention
Somatostatin vs. no intervention The decrease in incidences of
pancreatic fistula (RR 0.35, 95% CI 0.14–0.88), reduced number
of patients with any complications (RR 0.50, 95% CI 0.27–0.93)
and reduction in duration of hospital stay (MD -6.79 days, 95%
CI -10.65 to -2.94; mean hospital stay 22.1 days in the somatosta-
tin group vs. 27.6 days in controls) in the somatostatin group
compared with the control group were statistically significant.
There was no difference between the two groups in any of the
other outcomes.
Octreotide vs. no intervention The lower incidences of pan-
creatic fistula (RR 0.61, 95% CI 0.49–0.77) and abdominal collec-
tions (RR 0.61, 95% CI 0.42–0.89), lower number of
complications (rate ratio 0.66, 95% CI 0.55–0.80) and lower
number of patients with any complications (RR 0.68, 95% CI
0.58–0.80) in the octreotide group compared with the control
group were statistically significant. There was no difference in any
of the other outcomes between the two groups.
The only outcome in which the test for subgroup differences
was positive was that of hospital stay (P = 0.001).
Stratified by aetiologies
Malignancy Decreases in the incidence of pancreatic fistula (RR
0.52, 95% CI 0.35–0.77) and sepsis (RR 0.28, 95% CI 0.08–0.97),
number of complications (rate ratio 0.61, 95% CI 0.48–0.77) and
number of patients with complications (RR 0.60, 95% CI 0.45–
0.79) in the SA group over the control group were statistically
significant. The decrease in the duration of hospital stay in the SA
group over that in the control group (MD -7.57 days, 95% CI
-11.29 to -3.84; mean hospital stay 25.0 days in the SA group vs.
32.1 days in controls) was statistically significant (Fig. 5). There
was no difference in any of the other outcomes between the two
groups.
Chronic pancreatitis Reductions in the incidence of pancreatic
fistula (RR 0.40, 95% CI 0.24–0.64) and number of patients with
any complications (RR 0.54, 95% CI 0.38–0.77) in the interven-
tion group compared with the control group were statistically
significant. There was no difference in any of the other outcomes
between the two groups.
The only outcome in which the test for subgroup differences
was positive was hospital stay (P = 0.03).
Stratified by procedure
A planned subgroup analysis of distal pancreatectomy and pan-
creatic drainage procedures could not be performed as the data for
these procedures were not available from the trials. Only the sub-
group of patients undergoing pancreatoduodenectomy was
reported.
Pancreatoduodenectomy There was no statistically significant
difference between the SA and control group for any of the
outcomes.
Variations in statistical analysis
Adopting the random-effects model or calculating the risk differ-
ence did not change the results. Sensitivity analysis using empiri-
cal continuity correction factors39 was not performed because
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Figure 2 Comparison of somatostatin analogues vs. no intervention showing effects on (A) perioperative mortality, (B) re-operation rates and
(C) hospital stay. M-H, Mantel-Haenszel; 95% CI, 95% confidence interval, SD, standard deviation
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there were no statistically significant outcomes in the main com-
parison with zero event trials.
Reporting bias
The funnel plot of the primary outcomes did not show any report-
ing bias (Fig. 6). Egger’s linear regression approach to identifying
publication bias24 did not reveal any bias for the outcome perio-
perative mortality (P = 0.3199). This was not calculated for the
outcome re-operation because few trials included that outcome.
Discussion
Somatostatin analogues did not decrease rates of perioperative
mortality and re-operation in patients undergoing pancreatic
surgery. The main indication for re-operation is the presence of a
pancreatic fistula-associated sepsis or organ dysfunction.13 There
is no universal definition of pancreatic fistula or pancreatic leak
and incidences vary depending on the definitions used. An inter-
national study group of surgeons13 have graded postoperative
pancreatic fistulas by consensus as A, B and C. Grade A fistulas are
transient and do not have any clinical impact. Grade B fistulas
require alteration in the management of the patient. Grade C
fistulas require major alterations in the management of the
patient and usually indicate re-operation. Grade B and C fistulas
have significant clinical impact and may contribute to increased
morbidity and mortality. In this review, only trials in which data
on grade B or C fistulas were available separately from grade A
were included for the outcome of clinically significant pancreatic
fistula (grades B and C). The overall incidence of pancreatic fistula
was lower in the SA group. Only three trials distinguished between
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Figure 3 Comparison of somatostatin analogues vs. no intervention showing effects on pancreatic fistula rates. (A) Pancreatic fistula (all):
studies did not differentiate between clinically significant and clinically insignificant fistulas. (B) Pancreatic fistula (clinically significant):
studies included only clinically significant fistulas. M-H, Mantel-Haenszel; 95% CI, 95% confidence interval
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any pancreatic fistula and clinically significant pancreatic fis-
tula.26,27,33 There was no difference between the SA and control
groups in the incidence of clinically significant pancreatic fistula.
It is likely that some of the pancreatic fistulas that were reported in
the other trials were clinically significant. However, in the absence
of data on the proportion of these fistulas that were clinically
significant, such trials could not be included for the outcome
‘clinically significant pancreatic fistulas’ and could be included
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Figure 4 Comparison of somatostatin analogues vs. no intervention showing effects on perioperative complications. (A) Number of
complications. (B) Number with any complications. SE, standard error; M-H, Mantel-Haenszel; 95% CI, 95% confidence interval
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Figure 5 Comparison of somatostatin analogues vs. no intervention. Subgroup analysis stratified by different aetiologies: effects on hospital
stay. SD, standard deviation; 95% CI, 95% confidence interval
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only for the outcome ‘all pancreatic fistulas’. That only a few trials
were included under the outcome ‘clinically significant pancreatic
fistulas’ may explain the lack of any statistically significant differ-
ence between the SA and control groups. Alternatively, the lack of
a statistically significant difference may reflect the lack of effect. In
patients undergoing pancreatic surgery for malignancy, a decrease
in hospital stay was noted in the SA group. This suggests that SAs
decreased clinically significant fistulas in patients undergoing
pancreatic surgery for cancer.
Overall postoperative complications were lower in the interven-
tion group than the control group. However, there was no differ-
ence between the two groups in length of hospital stay in the main
analysis. The possible reasons for the absence of difference in total
hospital stay include a lack of effect of SAs with regard to inci-
dence of re-operation, anastomotic leak or clinically significant
pancreatic fistulas and the fact that pancreatic fistulas are often
managed at the patient’s home (as community-based treatment).
Pancreatic fistulas that are amenable to community-based treat-
ment may decrease the quality of life of the patients concerned
during the time they take to close, increase the length of the
convalescence period, thus causing a later return to work and
resulting in major cost implications for patients, patients’ carers
and patients’ employers, and increase the costs associated with the
provision of community-based treatment, despite the fact that
SAs do not appear to reduce hospital stay.
As far as the interventions were concerned, somatostatin must
be administered by continuous i.v. infusion for approximately 1
week. This can decrease the patient’s mobility. By contrast, oct-
reotide is administered subcutaneously thrice per day, allowing
good patient mobility. Its other advantage is that it can be admin-
istered even in patients with difficult venous access, thereby
increasing compliance. The adverse effects associated with the
intervention were mainly minor, such as pain at the injection site.
No serious adverse effects were reported in any of the trials. Of the
trials that reported the withdrawal of intervention, the treatment
was stopped in about 1.5% of the 540 patients. In high-income
countries, the cost of an entire course of octreotide is less than the
cost of 1 day in hospital. There was no difference in length of
hospital stay between the two groups in the main analysis.
However, the subgroup analysis revealed a shorter hospital stay in
the intervention group in the somatostatin (P = 0.0006) and
malignancy (P < 0.0001) subgroups. Only three trials were
included in each of these subgroups,27,28,34 one of which featured in
both subgroups.27 It is not clear whether the lower hospital stay in
the intervention group in these subgroups is because of the inter-
vention effect or because of the numerous subgroup analyses that
were performed. The lack of information on pancreatic fistula (i.e.
whether it was clinically significant or not) does not help us to
reach a conclusion. Patients with chronic pancreatitis have a lower
risk of postoperative complications than those with malignancy
and this may be because the tissue fibrosis usually seen in patients
with chronic pancreatitis facilitates the anastomotic procedure.34
This logical reasoning combined with the very low P-value
obtained suggests that the decrease in hospital stay in patients
undergoing pancreatic surgery for malignancy reflects the true
effect of SAs. Further evaluation of the cost-effectiveness of SAs in
pancreatic surgery is necessary.
Somatostatin analogues reduce perioperative complications
but do not reduce perioperative mortality. In patients undergoing
pancreatic surgery for malignancy, they shorten hospital stay.
Further adequately powered trials of low risk of bias are necessary.
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differently, depending on the reader’s perspectives and circum-
stances. Please consider the conclusions presented carefully. They
are the opinions of the review authors and are not necessarily
shared by the Cochrane Collaboration.
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